Unichem Laboratories has received USFDA approval to market alfuzosin hydrochloride extended release tablets, used in treating prostatic hyperlasia, in USA. The tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperlasia in adults. The product will be commercialised from Unichem’s Goa plant. The active pharmaceutical ingredients (API) for the product would also be made in-house at Pithampur plant. The company has a total of 20 abbreviated new drug application ( ANDA) approvals from the USFDA.
Company Profile : Unichem Laboratories Ltd
Leave a Reply